Kawasumi Laboratories Inc. announced consolidated earnings results for the first quarter ended June 30, 2016. For the period, the consolidated company reported net sales of ¥6,048 million, operating income of ¥309 million, ordinary income of ¥173 million, profit attributable to owners of the parent of ¥393 million or net income per share of ¥18.03 compared to net sales of ¥6,778 million, operating income of ¥365 million, ordinary income of ¥473 million, net income of ¥344 million or net income per share of ¥15.08 for the same period last year. Profit before income taxes was ¥170 million against ¥491 million a year ago. Net cash provided by operating activities was ¥778 million against ¥600 million a year ago. Purchase of property, plant and equipment was ¥616 million against ¥122 million a year ago. Purchase of intangible assets was ¥49 million against ¥14 million a year ago.

For the six months ending September 30, 2016, the company expects net sales of ¥12,500 million, operating income of ¥300 million, ordinary income of ¥300 million, profit attributable to owners of the parent of ¥500 million or net income per share of ¥22.92.

For the full year of fiscal year ending March 31, 2017, the company expects net sales of ¥25,700 million, operating income of ¥1,000 million, ordinary income of ¥1,000 million, profit attributable to owners of the parent of ¥1,100 million or net income per share of ¥50.42.